CMS Open Payments · Tool
Aurobindo Pharma USA, Inc. vs Novartis Gene Therapies, Inc. (fka Avexis, Inc.)
Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.
A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.
Compare Different Companies
Relationship comparison
Which recorded payment profile is more concentrated?
Novartis Gene Therapies, Inc. (fka Avexis, Inc.) has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 4,762, versus 2,662 for the other company. Its single largest recorded recipient represents 0.6% of that company's General Payments recipient total.
HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.
- Aurobindo Pharma USA, Inc.
- HHI 2,662 · top recipient 0.3%
- Ranked #621 of 1,838 companies by HHI
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)
- HHI 4,762 · top recipient 0.6%
- Ranked #391 of 1,838 companies by HHI
Payment Overview
Aurobindo Pharma USA, Inc.
- Total Payments
- $120.1K
- % of Industry
- 0.0%
- Transactions
- 137
- Avg per Transaction
- $876.46
- Recipients
- 137
- Avg per Recipient
- $876.46
- Payment Types
- 3
- Top Payment Type
- Consulting Fee
- Total Payments
- $120.0K
- % of Industry
- 0.0%
- Transactions
- 39
- Avg per Transaction
- $3.1K
- Recipients
- 15
- Avg per Recipient
- $8.0K
- Payment Types
- 3
- Top Payment Type
- Compensation for Services Other Than Consulting
Highlighted values indicate the higher figure for each metric.
Total payments compared
Aurobindo Pharma USA, Inc. vs Novartis Gene Therapies, Inc. (fka Avexis, Inc.) - total reported payments in CMS Open Payments PY2024
Payment Types Breakdown
Aurobindo Pharma USA, Inc.
98.1%
1.4%
0.5%
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)
57.9%
1.6%
0.6%
Top 5 General-Payment Recipients
This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.
Aurobindo Pharma USA, Inc.
- 1
Robert Cotes
$41,817.39 · 37 txns
- 2
John Kane
$40,578.83 · 40 txns
- 3
David Sykes
$19,377.54 · 26 txns
- 4
Kevin ZACHAROFF
$4,262.14 · 12 txns
- 5
CAROL TAMMINGA
$3,710.95 · 6 txns
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)
- 1
Univ Of Mi Hospitals & Hlth Ctrs
$40,397.44 · 2 txns
- 2
Ronald Reagan Ucla
$29,078.34 · 1 txns
- 3
JERRY MENDELL
$1,376.00 · 1 txns
- 4
SAUNDER BERNES
$565.00 · 1 txns
- 5
ANA TESI ROCHA
$165.05 · 2 txns
Summary Comparison
| Metric | Aurobindo Pharma USA, Inc. | Novartis Gene Therapies, Inc. (fka Avexis, Inc.) |
|---|---|---|
| Total Payments | $120.1K | $120.0K |
| % of Industry Total | 0.0% | 0.0% |
| Transaction Count | 137 | 39 |
| Avg per Transaction | $876.46 | $3.1K |
| Recipient Count | 137 | 15 |
| Avg per Recipient | $876.46 | $8.0K |
| Payment Type Count | 3 | 3 |
| Top Payment Type | Consulting Fee | Compensation for Services Other Than Consulting |
Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.